​The main project of Xavier Morelli's team is focused on the identification, understanding and targeting of protein-protein interaction in cancer signaling using structural and chemical biology technologies. He has published >50 publications and patented 4 applications related to the inhibition of protein-protein interactions. He is an actual member of the scientific committee of the 'Canceropole PACA', board member of the "GDR Chembioscreen" a national organization for chemical biology screening in France and has acted as secretary of the French Society of Chemoinformatics (SFCi). He has also acted as scientific board member of the Foundation ARC (national agency against cancer), associate editor of the journal BMC 'Pharmacology & Toxicology' and as editorial board member of several scientific journals. He is a regular consultant for pharmaceutical companies and a member of the PhD program committee of the School of Chemistry at the Aix-Marseille University.​